Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma

• Asıl Yazarlar: Han MA (Yazar), Shu Qiu (Yazar), Rongbiao Lu (Yazar), Peiying Feng (Yazar), Chun Lu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Sociedade Brasileira de Dermatologia, 2016-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.
• Notes: 0365-0596; 10.1590/abd1806-4841.20163875
• Keywords: Biological agents; Lymphoma, T-Cell, peripheral; Lymphoma, T-Cell, cutaneous; Lymphoma, primary cutaneous anaplastic large cell; Methotrexate; Dermatology; RL1-803
• Source: Anais Brasileiros de Dermatologia, Vol 91, Iss 3, Pp 368-371 (2016)

Abstract: Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.